Impact of interstitial changes on radiation pneumonitis after stereotactic body radiation therapy for lung cancer

Anticancer Research

Volumn 35, Issue 9, 2015, Pages 4909-4914

  Yoshitake, Tadamasa ^a   Shioyama, Yoshiyuki ^b   Asai, Kaori ^a   Nakamura, Katsumasa ^a   Sasaki, Tomonari ^a   Ohga, Saiji ^a   Kamitani, Takeshi ^a   Yamaguchi, Toshihiro ^a   Ohshima, Kaori ^a   Matsumoto, Keiji ^a   Kawanami, Satoshi ^a   Honda, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Kyushu International Heavy Ion Beam Therapy Center   (Japan)

Author keywords

Interstitial changes; Radiation pneumonitis; Stereotactic radiation therapy

Indexed keywords

C REACTIVE PROTEIN; KL 6 PROTEIN; LACTATE DEHYDROGENASE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE MARKER; DOSIMETRY; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL CHANGE; LUNG CANCER; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; RADIOTHERAPY PLANNING SYSTEM; STEREOTACTIC BODY RADIATION THERAPY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOSURGERY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOSURGERY;

EID: 84939607014     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, Sakamoto M, Mitsumori M, Shibuya K, Araki N, Yano S and Hiraoka M: Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63: 1427-1431, 2005.
2. Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, Drugge N, Ekberg L, Friesland S, Johansson KA, Lund JA, Morhed E, Nilsson K, Levin N, Paludan M, Sederholm C, Traberg A, Wittgren L and Lewensohn R: Outcome in a prospective phase II trial of medically inoperable stage I nonsmall-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol 27: 3290-3296, 2009.
3. Fakiris AJ, McGarry RC, Yiannoutsos CT, Papiez L, Williams M, Henderson MA and Timmerman R: Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 75: 677-682, 2009.
4. Wulf J, Haedinger U, Oppitz U, Thiele W, Mueller G and Flentje M: Stereotactic radiotherapy for primary lung cancer and pulmonary metastases: a noninvasive treatment approach in medically inoperable patients. Int J Radiat Oncol Biol Phys 60: 186-196, 2004.
5. Nuyttens JJ, van der Voort van Zyp NC, Verhoef C, Maat A, van Klaveren RJ, van der Holt B, Aerts J and Hoogeman M: Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int J Radiat Oncol Biol Phys 91: 337-343, 2015.
6. Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, van den Borne BE, Munsell MF, Hurkmans C, Berry DA, van Werkhoven E, Kresl JJ, Dingemans AM, Dawood O, Haasbeek CJ, Carpenter LS, De Jaeger K, Komaki R, Slotman BJ, Smit EF and Roth JA: Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 2015 (in press).
7. Borst GR, Ishikawa M, Nijkamp J, Hauptmann M, Shirato H, Onimaru R, van den Heuvel MM, Belderbos J, Lebesque JV and Sonke JJ: Radiation pneumonitis in patients treated for malignant pulmonary lesions with hypofractionated radiation therapy. Radiother Oncol 91: 307-313, 2009.
8. Yamashita H, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, Shiraishi K, Sasano N and Ohtomo K: Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2: 21-31, 2007.
9. Guckenberger M, Baier K, Polat B, Richter A, Krieger T, Wilbert J, Mueller G and Flentje M: Dose-response relationship for radiation-induced pneumonitis after pulmonary stereotactic body radiotherapy. Radiother Oncol 97: 65-70, 2010.
10. Stauder MC, Macdonald OK, Olivier KR, Call JA, Lafata K, Mayo CS, Miller RC, Brown PD, Bauer HJ and Garces YI: Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. Radiother Oncol 99: 166-171, 2011.
11. Song JW, Hong SB, Lim CM, Koh Y and Kim DS: Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 37: 356-363, 2011.
12. Shioyama Y, Nakamura K, Anai S, Sasaki T, Ooga S, Saku M, Urashima Y, Yoshitake T, Toba T, Terashima H and Honda H: Stereotactic radiotherapy for lung and liver tumors using a body cast system: setup accuracy and preliminary clinical outcome. Radiat Med 23: 407-413, 2005.
13. Yoshitake T, Nakamura K, Shioyama Y, Nomoto S, Ohga S, Toba T, Shiinoki T, Anai S, Terashima H, Kishimoto J and Honda H. Breath-hold monitoring and visual feedback for radiotherapy using a charge-coupled device camera and a headmounted display: system development and feasibility. Radiat Med 26: 50-5, 2008.
14. National Cancer Institute: Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS. NIH publication # 09-7473, 2009.
15. Yamashita H, Kobayashi-Shibata S, Terahara A, Okuma K, Haga A, Wakui R, Ohtomo K and Nakagawa K: Prescreening based on the presence of CT-scan abnormalities and biomarkers (KL-6 and SP-D) may reduce severe radiation pneumonitis after stereotactic radiotherapy. Radiat Oncol 5: 32-40, 2010.
16. Sanuki N, Ono A, Komatsu E, Kamei N, Akamine S, Yamazaki T, Mizunoe S and Maeda T: Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res 53: 110-116, 2012.
17. Yamaguchi S, Ohguri T, Ide S, Aoki T, Imada H, Yahara K, Narisada H and Korogi Y: Stereotactic body radiotherapy for lung tumors in patients with subclinical interstitial lung disease: the potential risk of extensive radiation pneumonitis. Lung Cancer 82: 260-265, 2013.
18. Ueki N, Matsuo Y, Togashi Y, Kubo T, Shibuya K, Iizuka Y, Mizowaki T, Togashi K, Mishima M and Hiraoka M: Impact of pretreatment interstitial lung disease on radiation pneumonitis and survival after stereotactic body radiation therapy for lung cancer. J Thorac Oncol 10: 116-125, 2015.
19. Barriger RB, Forquer JA, Brabham JG, Andolino DL, Shapiro RH, Henderson MA, Johnstone PA and Fakiris AJ: A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys 82: 457-462, 2012.
20. Yamashita H, Takahashi W, Haga A and Nakagawa K: Radiation pneumonitis after stereotactic radiation therapy for lung cancer. World J Radiol 6: 708-715, 2014.
21. Ong CL, Palma D, Verbakel WF, Slotman BJ and Senan S: Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. Radiother Oncol 97: 431-436, 2010.
22. van den Blink B, Wijsenbeek MS and Hoogsteden HC: Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther 23: 515-520, 2010.
23. Ohnishi H, Yokoyama A, Kondo K, Hamada H, Abe M, Nishimura K, Hiwada K and Kohno N: Comparative study of KL-6, surfactant protein-A, surfactant protein-D, and monocyte chemoattractant protein-1 as serum markers for interstitial lung diseases. Am J Respir Crit Care Med 165: 378-381, 2002.
24. Hara R, Itami J, Komiyama T, Katoh D and Kondo T: Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 125: 340-344, 2004.
25. Iwata H, Shibamoto Y, Baba F, Sugie C, Ogino H, Murata R, Yanagi T, Otsuka S, Kosaki K, Murai T and Miyakawa A: Correlation between the serum KL-6 level and the grade of radiation pneumonitis after stereotactic body radiotherapy for stage I lung cancer or small lung metastasis. Radiother Oncol 101: 267-270, 2011.